Candriam Equities L Oncology I GBP Cap
Healthcare and BiotechnologyPricing frequency
Daily
Dealing cut off time
09:45
Type
SICAV
Yield
–
NAV
£2,767.13
Income frequency
-
Ongoing charge
1%
Latest actual NAV date
12-11-2026
ISIN
LU1864482515
UCITS
Yes
Growth of 10k
Asset allocation
Top 10 holdings
| Holdings 30/04/2026 | % of assets |
|---|---|
| Eli Lilly and Co | 7.06 |
| AstraZeneca PLC | 4.87 |
| Novartis AG Registered Shares | 4.01 |
| Thermo Fisher Scientific Inc | 3.76 |
| Merck & Co Inc | 3.65 |
| Pfizer Inc | 3.16 |
| AbbVie Inc | 3.05 |
| McKesson Corp | 3.01 |
| Gilead Sciences Inc | 2.87 |
| Bristol-Myers Squibb Co | 2.56 |
Investment objective
The objective of the sub-fund is to use discretionary management to benefit from the performance of the market in global equities of companies in the field of oncology (cancer research, diagnosis, treatment, etc.) in order to respond to one of the serious long-term challenges of sustainable development. The sub-fund therefore seeks to produce a return for investors while generating a positive social impact over the long term, by selecting companies that address certain societal challenges and mobilise resources in the fight against cancer.
This product is based overseas and is not subject to UK sustainable investment labelling and disclosure requirements. Learn more about SDR.